Breaking News Instant updates and real-time market news.

2019-02-13 09:01:27

PCG

PG&E

$15.43

1.08 (7.53%)

, FCX

Freeport McMoRan

$11.49

-0.04 (-0.35%)

…09:01

02/13/19

02/13

09:01

02/13/19

09:01

Fly Intel: Pre-market Movers

HIGHER: PG&E (PCG), up 2% after BlueMountain Capital Management provided an update on its progress to nominate a full slate of new directors to replace the current Board of Directors of PG&E in its entirety... Freeport McMoRan (FCX), up 5% after Morgan Stanley analyst Piyush Sood upgraded the stock to Overweight from Equal Weight, noting that his firm's Metals & Mining team expects copper market tightness to emerge beginning in Q2... Geron (GERN), up 15% after BTIG analyst Thomas Shrader initiated the stock with a Buy rating and a price target of $4.00. The analyst says the stock has been "left for dead" even though the study of Imetelstat showed clear indications of efficacy. UP AFTER EARNINGS: Hilton (HLT), up 4%... Interpublic Group (IPG), up 5%... Lattice Semiconductor (LSCC), up 15%. DOWN AFTER EARNINGS: Dish (DISH), down 7%... Black Knight (BKI), down 1%... ACCO Brands (ACCO), down 18%... Teva (TEVA), down 12%... Natus Medical (BABY), down 18%. ALSO LOWER: Clearway Energy (CWEN), down 5% after Guggenheim analyst Shahriar Pourreza downgraded shares to Sell from Neutral. After his discussions with key stakeholders and the management, the analyst expects the company to announce a dividend cut in the next few days.

PG&E shares should not be driven by possible FERC contract ruling, says Mizuho

Speculation about a possible court ruling on whether the Federal Energy Regulatory Commission has the authority to block the rejection of contracts under the filed rate doctrine principal should not be a driver in the value of PG&E shares, Mizuho analyst Paul Fremont tells investors in a research note titled "50 Ways to Leave Your Lover." The analyst believes the rejection of purchase power agreements contracts would not add anything to the long-term equity value of PG&E when it emerges from bankruptcy. However, potential savings, which would likely be significant, could provide leverage in negotiations with California State politicians and regulators prior to exiting bankruptcy, adds Fremont. He attributes the stock's current value to the market anticipating a ruling by the bankruptcy court in the next month on whether FERC has the authority to interfere with PG&E's right to reject contracts under the filed rate doctrine principal. The analyst keeps a Neutral rating on PG&E with a $15 price target.

02/11/19

02/11/19DOWNGRADETarget $65Market Perform

Edison International downgraded to Market Perform at Wells Fargo

As previously reported, Wells Fargo analyst Neil Kalton downgraded Edison International (EIX) to Market Perform from Outperform to reflect his increasing pessimism that there would be meaningful change to California's inverse condemnation law in the near-term. As a result, investors could remain exposed to substantial tail risk in the event the company's infrastructure is implicated in a catastrophic wildfire, he contends. Positively, Kalton continues to believe PG&E's (PCG) bankruptcy filing could be the catalyst that prompts substantive change to IC. The analyst also trimmed his price target on Edison International's shares to $65 from $66.

01/28/19

WOLF

01/28/19UPGRADETarget $29WOLFOutperform

PG&E upgraded to Outperform from Peer Perform at Wolfe Research

Wolfe Research analyst Steven Fleishman upgraded PG&E to Outperform from Peer Perform while acknowledging that the company will likely file bankruptcy tomorrow, stating that he views bankruptcy "as a path to maximize equity value, not eliminate it." He sees bankruptcy providing a fairer forum to resolve claims in federal courts, a quicker path to challenge inverse condemnation rules and a cleaner path for asset sales, Fleishman tells investors. He maintains a $29 price target on PG&E shares, adding that he believes much of the negatives of bankruptcy have already been priced into the stock.

JPMorgan analyst Christopher Turnure says yesterday's report from the California Department of Forestry and Fire Protection is a "clear positive" for PG&E. With the report finding that PG&E wires were not the source of ignition for Tubbs Fire, the analyst now assumes the company is largely absolved of an estimated $7B of liabilities. Despite this favorable finding, PG&E continues to face roughly $28B of gross fire liabilities, Turnure tells investors in a research note. The primary challenges are that potential liabilities continue to exceed the financing capacity of the company, adds the analyst. He believes PG&E will face years of litigation stemming from the 2017-2018 wildfires absent its potential bankruptcy filing. Turnure raised his price target for the shares to $11 from $10 and keeps a Neutral rating on PG&E. The stock closed yesterday up 74%, or $5.92, to $13.95.

FCXFreeport McMoRan

$11.49

-0.04 (-0.35%)

01/09/19

01/09/19INITIATION

Fly Intel: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CarGurus (CARG) initiated with an Outperform at Oppenheimer. 2. Callaway Golf (ELY) and Acushnet Holdings (GOLF) were initiated with an Equal Weight at Stephens. 3. MVB Financial (MVBF) initiated with a Market Perform at Keefe Bruyette. 4. U.S. Steel (X) initiated with a Market Perform at Cowen. 5. Freeport McMoRan (FCX) initiated with a Neutral at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

As previously reported, Morgan Stanley analyst Piyush Sood upgraded Freeport McMoRan to Overweight from Equal Weight, noting that his firm's Metals & Mining team expects copper market tightness to emerge beginning in Q2, given falling global production, low visible inventories and improved demand from China. Freeport's earnings sensitivity to copper is still the highest among its peers, said Sood, who sees the stock emerging as "the go-to large-cap stock for exposure to a copper price rally." Concerns about Freeport's ability to ramp production from 2019-21 are overblown, added the analyst, who lowered his price target on the shares to $14 from $16, citing a lower multiple to reflect the overall compression in multiples across equities and management's newly disclosed expectations around costs.

02/12/19

JEFF

02/12/19NO CHANGETarget $25JEFFBuy

Jefferies sees 'strong recovery' for Freeport McMoRan after 2019

Until recently, investor sentiment regarding Freeport McMoRan had been negative following a challenging 2018, Jefferies analyst Christopher LaFemina tells investors in a research note. Further, the analyst believes the consensus view is that 2019 will be another difficult year for Freeport due to low volumes, high unit costs, high capex and a low copper price. LaFemina agrees that 2019 will be a "trough year" for Freeport, but he also expects a "strong recovery" in EBITDA and free cash flow after 2019. As such, the analyst reiterates a Buy rating on the shares with a $25 price target.

B. Riley FBR analyst George Zavoico upgraded Geron (GERN) to Buy from Neutral and raised his price target for the shares to $3.25 from $1.50. The analyst believes investors should focus on the pivotal Phase III trial of imetelstat. Geron is initiating the pivotal portion of its Phase 3 trial in mid-year, which could lead to FDA approval in 2023, says Zavoico. He sees U.S. sales reaching $250M in 2024 and $750M in 2026. The drug "could meet an unmet medical need and provide a meaningful clinical benefit" for myelodysplastic syndrome patients, Zavoicotells investors in a research note. He expects both imetelstat and Celgene (CELG) and Acceleron's (XLRN) Luspatercept to be approved for MDS and be "widely used in treating mostly different subgroups." Shares of Geron are up 11%, or 11c, to $1.14 in premarket trading.

01/31/19

RILY

01/31/19UPGRADETarget $3.25RILYBuy

Geron upgraded to Buy from Neutral at B. Riley FBR

B. Riley FBR analyst George Zavoico upgraded Geron to Buy and raised his price target for the shares to $3.25 from $1.50. The analyst believes investors should focus on the pivotal Phase III trial of imetelstat.

01/31/19

01/31/19UPGRADE

Fly Intel: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Outperform from Neutral at Credit Suisse and to Buy from Hold at Argus. 2. Tiffany (TIF) upgraded to Overweight from Neutral at Atlantic Equities with analyst Daniela Nedialkova saying the pullback has been largely driven by macro concerns while fundamentals of the brand are strong and preliminary FY19 guidance is conservative. 3. Scotts Miracle-Gro (SMG) upgraded to Neutral from Underweight at JPMorgan with analyst Jeffrey Zekauskas citing valuation. 4. Geron (GERN) upgraded to Buy from Neutral at B. Riley FBR with analyst George Zavoico saying he believes investors should focus on the pivotal Phase III trial of imetelstat. 5. Ralph Lauren (RL) upgraded to Outperform from Market Perform at Telsey Advisory with analyst Dana Telsey saying the company's improving sakes, combined with ongoing margin expansion, should bolster its earnings. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

02/12/19

BTIG

02/12/19INITIATIONTarget $4BTIGBuy

Geron initiated with a Buy at BTIG

BTIG analyst Thomas Shrader initiated Geron with a Buy rating and a price target of $4.00. The analyst says the stock has been "left for dead" even though the study of "Imetelstat - a telomerase inhibitor active in the treatment of highly transfusion-dependent MDS and r/r myelofibrosis" showed clear indications of efficacy. Shrader notes the company will take over the development of Imetelstat with pivotal trials starting this year and may attract "investor interest as corroborative pivotal readouts approach."

Wells Fargo analyst Jeffrey Donnelly downgraded his sector rating on the Lodging sector to Underweight from Market Weight. Deceleration in the outlook for domestic and global growth, rising labor costs and turnover, as well as the yield curve signaling higher risk of a nearing recession, will collectively make it challenging for the hotel sector to deliver accelerating growth and outperform, Donnelly tells investors in a research note. Within the sector, the analyst believes hotel brands are better positioned to outperform the hotel real estate investment trusts "given their healthy unit growth and lower sensitivity to economic shifts in the short run." He lowered his price target for Market Perform-rated Choice Hotels (CHH) to $80 from $82, for Outperform-rated Hilton (HLT) to $74 from $81, for Market Perform-rated Marriott (MAR) to $119 from $127, for Market Perform-rated RLJ Lodging Trust to $19 from $20, for Market Perform-rated Sunstone Hotel (SHO) to $15 from $16 and for Market Perform-rated Xenia Hotels (XHR) to $20 from $21.

11/05/18

11/05/18DOWNGRADE

On The Fly: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Starbucks (SBUX) downgraded to Sell from Hold at DZ Bank. 2. Encana (ECA) downgraded to Equal Weight from Overweight at Morgan Stanley and to Market Perform from Outperform at BMO Capital. 3. Hilton (HLT) downgraded to Hold from Buy at Argus with analyst John Staszak saying that while the company is seeing success from its franchised business model, some of its markets are facing more challenging economic conditions and competition from other hoteliers and Airbnb is growing tighter. 4. Motorola Solutions (MSI) downgraded to Hold on valuation at Gabelli with analyst Hendi Susanto citing valuation. 5. UMC (UMC) downgraded to Sell from Underperform at CLSA with the firm's analyst citing the U.S. federal grand jury indictment into the company's potential involvement in IP-theft from Micron (MU). This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

11/05/18

ARGS

11/05/18DOWNGRADEARGSHold

Hilton downgraded to Hold at Argus on macro concerns and tighter competition

As reported earlier, Argus analyst John Staszak downgraded Hilton to Hold from Buy, saying that while the company is seeing success from its franchised business model, some of its markets are facing more challenging economic conditions and competition from other hoteliers and Airbnb is growing tighter. The analyst also lowers his FY18 EPS view by 5c to $2.75 and FY19 by 6c to $3.10, adding that Hilton stock looks "fully valued" at a forward earnings multiple of 23.4-times relative to the peer average of 17.0-times.

11/05/18

ARGS

11/05/18DOWNGRADEARGSHold

Hilton downgraded to Hold from Buy at Argus

IPGInterpublic Group

$21.67

-0.13 (-0.60%)

01/18/19

01/18/19DOWNGRADE

Fly Intel: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Signet Jewelers (SIG) downgraded to Sell from Neutral at Citi with analyst Paul Lejuez saying in what was one of the strongest years from the consumer since the recession, Signet's comps and margins have been under pressure. 2. Casa Systems (CASA) downgraded to Equal Weight from Overweight at Morgan Stanley and to Hold from Buy at Stifel. 3. Sandy Spring Bancorp (SASR) downgraded to Hold from Buy at Sandler O'Neill and to Market Perform from Outperform at Keefe Bruyette. 4. Interpublic Group (IPG) downgraded to Sector Perform from Outperform at RBC Capital with analyst Steven Cahall saying he expects the company's organic growth to decelerate in 2019 after "recent account losses," stating that after a "fantastic" organic growth rate of 4.6%, Interpublic Group is now facing tougher comps. 5. Nautilus (NLS) downgraded to Neutral from Buy at Sidoti, DA Davidson, and B. Riley FBR, as well as to Hold from Buy at Lake Street. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

01/18/19

RBCM

01/18/19DOWNGRADETarget $24RBCMSector Perform

Interpublic Group cut to Sector Perform at RBC Capital on lower organic growth

As reported earlier, RBC Capital analyst Steven Cahall downgraded Interpublic Group to Sector Perform and lowered his price target to $24 from $28. The analyst expects the company's organic growth to decelerate in 2019 after "recent account losses", stating that after a "fantastic" organic growth rate of 4.6%, Interpublic Group is now facing tougher comps. In reducing his growth outlook to 2.3% from 3.0% - below the consensus 2.5% - Cahall adds that he doesn't expect Acxiom to contribute until Q4 of this year.

01/17/19

RBCM

01/17/19DOWNGRADETarget $24RBCMSector Perform

Interpublic Group downgraded to Sector Perform from Outperform at RBC Capital

RBC Capital analyst Steven Cahall downgraded Interpublic Group to Sector Perform from Outperform and lowered his price target to $24 from $28.

01/07/19

PIVT

01/07/19UPGRADETarget $25PIVTBuy

Interpublic Group upgraded to Buy from Hold at Pivotal Research

Pivotal Research analyst Brian Wieser upgraded Interpublic Group to Buy and raised his price target for the shares to $25 from $22. With the recent purchase of Acxiom's AMS business, Interpublic is "significantly better-positioned to pitch increasingly important data-related services to clients," Wieser tells investors in a research note. He sees more than 15% upside in the shares.

LSCCLattice Semiconductor

$8.17

0.22 (2.77%)

02/13/19

SUSQ

02/13/19UPGRADETarget $11SUSQPositive

Lattice Semiconductor upgraded to Positive at Susquehanna

As reported previously, Susquehanna analyst Christopher Rolland upgraded Lattice Semiconductor to Positive form Neutral. The analyst cited evidence of a turnaround and growing opportunities in AI, 5G, and server security. The analyst also believes its analyst day in May could serve as a catalyst as the company could offer guidance for high single-digit revenue growth, improved gross margins and operating leverage. Rolland raised his price target to $11 from $8 on Lattice Semiconductor shares.

02/13/19

SUSQ

02/13/19UPGRADESUSQPositive

Lattice Semiconductor upgraded to Positive from Neutral at Susquehanna

12/14/18

12/14/18UPGRADE

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dollar Tree (DLTR) upgraded to Outperform from Market Perform at Bernstein with analyst Brandon Fletcher saying while he still wants to see activism, he thinks management has done "enough" at the current valuation to make the grade. 2. Lattice Semiconductor (LSCC) upgraded to Outperform from Neutral at Baird with analyst Tristan Gerra saying Lattice has a highly defensible business model, in need of improved execution. 3. Procter & Gamble (PG) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Dara Mohsenian saying the upgrade is based on "broad-based market share momentum, an improving gross margin outlook, and greater earnings achievability are not adequately reflected in relative valuation vs. peers." 4. Regeneron (REGN) upgraded to Conviction Buy from Neutral at Goldman Sachs with analyst Terence Flynn saying he sees 25% upside after boosting his price target for the shares to $472 from $415. 5. Bausch Health (BHC) upgraded to Buy from Neutral at H.C. Wainwright analyst Raghuram Selvaraju saying now is an "appropriate time to become more bullish on the story." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Jefferies analyst Mark Lipacis raised his price target for Lattice Semiconductor to $10.50 after the company reported in-line Q4 results and provided a Q1 revenue outlook above consensus. The analyst thinks Lattice has a three-year earnings per share power that approaches $1.00. Further, the stock has downside support as the only remaining small-cap FPGA pure play in a consolidating industry, Lipacis tells investors in a research note. He says Lattice Semiconductor is his top small-cap pick.

HSBC analyst Sunil Rajgopal downgraded Dish (DISH) to Reduce from Hold and cut his price target on the shares to $24 from $38, advocating that investors choose "sturdy carriers" such as Verizon (VZ), T-Mobile (TMUS), AT&T (T) and Comcast (CMCSA). For 2019, Rajgopal expects more fragmentation in the content/pay-TV business as more players enter the OTT content market and he expects the pay TV base to shrink further.

01/25/19

01/25/19DOWNGRADE

Fly Intel: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Intel (INTC) downgraded to Hold from Buy at Needham and to Neutral from Positive at Susquehanna. 2. Hawaiian Holdings (HA) downgraded to Hold from Buy at Deutsche Bank with analyst Michael Linenberg saying he sees a more challenging competitive backdrop in Hawaiian's core markets by the June quarter. 3. Illumina (ILMN) downgraded to Hold from Buy at Deutsche Bank with analyst Dan Leonard saying forward revenue expectations lack upside potential while the "pace of newsflow to motivate further enthusiasm" for the company's total addressable market opportunity could slow. 4. Dish (DISH) downgraded to Reduce from Hold at HSBC with analyst Sunil Rajgopal saying he expects more fragmentation in the content/pay-TV business as more players enter the OTT content market and he expects the pay TV base to shrink further. 5. Thomson Reuters (TRI) downgraded to Sector Perform from Outperform at Scotiabank. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ACCOACCO Brands

$9.17

0.25 (2.80%)

05/01/18

BWSF

05/01/18NO CHANGETarget $18BWSFStrong Buy

BWS 'highly positive' on ACCO Brands after Q1 results

BWS Financial analyst Hamed Khorsand says he's "highly positive" on shares of ACCO Brands following the company's Q1 results. He would be buyer of the shares at current levels and believes the investment story is "beginning to come together." The analyst keeps a Buy rating on ACCO Brands with an $18 price target.

Barrington analyst Kevin Steinke notes that ACCO Brands' Q3/18 sales declined 4.7% year over year driven by North America, in which sales declined 8.8% organically due largely to a substantial decrease in sales to wholesalers resulting from ongoing consolidation in that channel, and says the company reduced full-year 2018 sales growth given inflationary pressures, unfavorable currency trends and headwinds from wholesaler channel consolidation. However, Steinke believes issues behind Q3 shortfall and guidance reduction appear transitory. He reiterates an Outperform rating and $13 price target on the shares.

02/15/18

BRRR

02/15/18NO CHANGEBRRR

ACCO Brands earnings, guidance beat expectations, says Barrington

Barrington analyst Kevin Steinke reiterated an Outperform rating and $16 price target on ACCO Brands after the company's Q4 results and guidance both came in ahead of expectations, and ACCO initiated a 6c per share quarterly dividend and authorized and additional $100M for share repurchases. Steinke believes ACCO will continue a "balanced approach to capital allocation that includes organic investments, debt reduction, acquisitions, dividends and share repurchases."

TEVATeva

$19.12

0.31 (1.65%)

01/23/19

01/23/19UPGRADE

Fly Intel: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Walmart (WMT) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Simeon Gutman citing his belief that Walmart U.S. can now generate sales growth without sacrificing margins, unlike most retailers. 2. Teva (TEVA) upgraded to Buy from Neutral at UBS and to Neutral from Underweight at Piper Jaffray. 3. D.R. Horton (DHI) upgraded to Buy from Neutral at Mizuho with analyst Haendel St. Juste saying stock selectivity is becoming more important in these latter stages of the housing cycle and larger platforms with price point diversification and strong balance sheets will be rewarded. 4. Logitech (LOGI) upgraded to Overweight from Neutral at JPMorgan and to Hold from Sell at Maxim. 5. Lamb Weston (LW) upgraded to Buy from Hold at Stifel with analyst Christopher Growe saying he is confident in the "growth profile of the business continuing amidst the very strong operating conditions in the category." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

02/01/19

WELS

02/01/19NO CHANGETarget $46WELSMarket Perform

Perrigo's ProAir opportunity 'may be vaporizing,' says Wells Fargo

Wells Fargo analyst David Maris noted that GlaxoSmithKline (GSK) launched an authorized generic of Ventolin on January 15 and he has now learned that Teva (TEVA) may have "surprisingly launched" an authorized generic of ProAir in response to the generic Ventolin pressure prior to Perrigo's (PRGO) approval. Pricing pressure from generic Ventolin, in addition to the launch of an authorized generic well ahead of Perrigo's own generic ProAir launch, seem to have significantly diminished Perrigo's generic ProAir opportunity, Maris tells investors. He keeps a Market Perform rating and $46 price target on Perrigo shares.

Piper Jaffray analyst Christopher Raymond kept an Overweight rating and $220 price target on Amgen (AMGN) following a Reuters report from earlier on Friday which stated that CVS (CVS) has excluded Amgen's Aimovig from its formulary. The analyst called the report "Friday afternoon clickbait" and noted that while CVS currently provides preferred status to Teva's (TEVA) Ajovy and Eli Lilly's (LLY) Emgality, this was made public in late 2018. In a check with management, Raymond found out the decision only encompasses about one-third of CVS network, that CVS is actively working to improve this access, and that 70% of commercial migraine patients have contracted access to Aimovig. Raymond concluded that this was "not something to worry about" in his view, and did not change his Q4, FY19, or FY20 estimates on Aimovig. In Friday trading, shares of Amgen were down just over 1% to $198.77.

After Novartis' (NVS) Sandoz generics unit reported Q4 sales were down 2% in constant currency, due to a 7% decline in price and 5% increase in volume, Wells Fargo analyst David Maris noted that the majority of the price erosion came from the U.S. While the 2% decline was a sequential improvement from down 4% in Q3, Novartis was up against an easy comparison in the year ago period, Maris added. His view is that the U.S. generic market has not materially changed or improved at this point and he contends the report has a "neutral to negative read-through" relative to investors' expectations for Mylan (MYL) and Teva (TEVA).

BABYNatus Medical

$29.87

-0.065 (-0.22%)

07/12/18

ROTH

07/12/18NO CHANGEROTH

Roth maintains Buy rating on Natus, says CEO change 'not a surprise'

Natus Medical announced Wednesday after the close that CEO Jim Hawkins is retiring and will be immediately replaced by CFO Jonathan Kennedy, and that Natus Q2 revenue guidance range was tightened to $130M-$131M from $129M-131M. Roth Capital analyst Scott Henry said the announcement was "not a surprise," added that the internal choice signals the "business is stable," and concluded that he was encouraged that the transition was not used to lower guidance. Henry maintained a Buy rating and $39 price target on Natus Medical shares, calling it a "good value and turnaround story."

02/27/18

ROTH

02/27/18INITIATIONTarget $39ROTHBuy

Natus Medical resumed with a Buy at Roth Capital

Roth Capital analyst Scott Henry resumed coverage of Natus Medical with a Buy rating and $39 price target as he believes the recent selloff of the shares following its Q4 earnings miss presents a buying opportunity for investors.

As previously reported, Guggenheim analyst Shahriar Pourreza downgraded Clearway Energy to Sell from Neutral and lowered his price target to $11 from $17. The analyst expects the company to announce a dividend cut in the next few days after his discussions with key stakeholders and the management, adding that "at a minimum", the company's cash may be "locked up at the project level for a pronounced period of time". Pourreza also lowers his forecast for Clearway Energy 2019 EBITDA to $818.6M from $1.07B.

01/07/19

GUGG

01/07/19DOWNGRADEGUGGNeutral

Clearway Energy downgraded to Neutral at Guggenheim

As previously reported, Guggenheim downgraded Clearway Energy to Neutral from Buy and cut its price target to $17 from $22. Analyst Shahriar Pourreza expects Clearway shares to work but said it will take time as more comfort is gained with the sponsor, contract quality, and pipeline opportunities.